Cambridge Antibody Technology Announces Data From Phase I Clinical Trial of CAT-354
Advertisement
Cambridge Antibody Technology announced that preliminary results of a Phase I clinical trial of CAT-354, a human anti-IL13 monoclonal antibody being studied as a potential treatment for severe asthma, showed CAT-354 to be well tolerated with no safety concerns identified.
The objective of the trial, which commenced in September 2004, was to assess the safety, tolerability and pharmacokinetics of CAT-354. It was a double-blind, placebo-controlled, rising single dose intravenous study in 34 mild asthmatic patients. Preliminary results showed that CAT-354 was well tolerated at all doses and there were no identified safety concerns; pharmacokinetics were as anticipated. The trial results will be submitted to an appropriate scientific meeting in due course.
Based on these results, CAT is planning to start a clinical pharmacology study in the fourth quarter of 2005. This is being planned as a repeat dose allergen challenge study in patients with asthma.
Patrick Round, VP Development at CAT, commented: "CAT-354 is an important product candidate for CAT and this trial was the first clinical step in its development as a potential treatment for severe asthma. We are encouraged by these preliminary results and are now moving forward with plans for a second clinical trial."
Other news from the department research and development
